Dry Eye, Sjogren Syndrome
Conditions
Keywords
Dry eye, Sjogren Syndrome, Insulin, Autologous Serum
Brief summary
Introduction: Dry Eye Disease (DED) of autoimmune origin is often severe and resistant to conventional treatments, necessitating alternative therapeutic options. Autologous Serum Eye Drops (ASED) have gained recognition for their biochemical and biomechanical properties, which closely mimic those of human tears. These properties make ASED an effective treatment for DED. Furthermore, topical insulin has demonstrated anti-inflammatory effects and promotes epithelial cell proliferation, differentiation, and migration, all of which contribute to maintaining ocular surface stability. As a result, insulin may serve as a valuable adjunct in treating moderate to severe autoimmune DED. Purpose: This study aims to assess and compare the effectiveness of autologous serum eye drops (group 1) and autologous serum eye drops combined with insulin (group 2) in improving the clinical signs and symptoms of moderate to severe DED in patients with autoimmune diseases, particularly those with Sjögren's Syndrome.
Detailed description
Introduction: Dry Eye Disease (DED) of autoimmune origin is often severe and resistant to conventional treatments, necessitating alternative therapeutic options. Autologous Serum Eye Drops (ASED) have gained recognition for their biochemical and biomechanical properties, which closely mimic those of human tears. These properties make ASED an effective treatment for DED. Furthermore, topical insulin has demonstrated anti-inflammatory effects and promotes epithelial cell proliferation, differentiation, and migration, all of which contribute to maintaining ocular surface stability. As a result, insulin may serve as a valuable adjunct in treating moderate to severe autoimmune DED. Purpose: This study aims to assess and compare the effectiveness of autologous serum eye drops (group 1) and autologous serum eye drops combined with insulin (group 2) in improving the clinical signs and symptoms of moderate to severe DED in patients with autoimmune diseases, particularly those with Sjögren's Syndrome.
Interventions
1 UI/ml of insulin added to the autologous serum formulation.
OTHERAutologous serum
Autologous Serum
Sponsors
Instituto de Oftalmología Fundación Conde de Valenciana
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Intervention model description
A randomized, single-blinded clinical trial will include patients aged 18 years and older who are diagnosed with moderate to severe DED associated with primary (PSS) or secondary (SSS) Sjögren's Syndrome. Both groups will receive ASED at a concentration of 30%. In group 2, 1 UI/ml of insulin will be added to the ASED formulation. The dosage will consist of one drop every 6 hours for 30 days in both groups. The following parameters will be evaluated at baseline (day 0), day 10, and day 30 of treatment: best corrected visual acuity (BCVA), ocular surface staining (Van-Bijsterveld score), Schirmer test, non-invasive tear break-up time (NITBUT), tear meniscus height (TMH), bulbar conjunctival hyperemia (BCH), and Ocular Surface Disease Index (OSDI) score. Statistical analysis will be performed using ANOVA for time/group comparisons with STATA 18.0 software.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Inclusion criteria included men and women aged 18 years or older with a diagnosis of primary\[ and secondary SS confirmed by a rheumatologist using the 2016 ACR-EULAR diagnostic criteria, and moderate to severe DED. Moderate to severe DED was classified using the following standardized parameters: Ocular Surface Disease Index (OSDI) ≥ 23 points, ocular surface staining according to the Van Bijsterveld score ≥ 4 points, non-invasive tear break-up time (NITBUT) ≤ 7 seconds, and tear meniscus height (TMH) ≤ 0.3 mm, measured with the Keratograph 5M (Oculus, Wetzlar, Germany). Participants were required to be willing to comply with the study protocol and follow-up schedule.
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OSDI | From enrollment, 10 days and 30 days after starting treatment. | Ocular Surface Disease Index |
Secondary
| Measure | Time frame |
|---|---|
| Ocular surface staining (Van-Bijsterveld score) | From enrollment, 10 days and 30 days after starting treatment. |
| Schirmer test | From enrollment, 10 days and 30 days after starting treatment. |
| non-invasive tear break-up time (NITBUT) | From enrollment, 10 days and 30 days after starting treatment. |
| Tear meniscus height (TMH) | From enrollment, 10 days and 30 days after starting treatment. |
Countries
Mexico
Outcome results
None listed